Table 1.
Study characteristics.
| PBT | SBRT | p value | |
|---|---|---|---|
| Studies (total n) | 9 | 72* | – |
| Patients (total n) | 614 | 7291 | – |
| Gender (% male) | 0.23 | ||
| Median (range) | 69% (20%, 87%) | 58% (20%, 95%) | |
| Median age (SE) | 75.75 (2.51) | 74.09 (0.86) | 0.53 |
| ECOG PS 0-1/ KPS 80–100 | |||
| Median (range) | 89% (60%, 98%) | 78% (24%, 100%) | 0.23 |
| Pathological diagnosis | |||
| Median (range) | 100% (0,100%) | 100% (0,100%) | 0.97 |
| PET/CT staging (%) | 71% | 81% | 0.44 |
| Treatment Period (year) | |||
| Median (SE) | 2006(1.08) | 2007(0.36) | 0.37 |
| Operability% | 38% | 16% | 0.07 |
| Median follow up (months) | |||
| Mean (SE) | 39.99 (3.82) | 27.79 (1.29) | 0.003 |
| Median tumor size (cm) | |||
| Mean (SE) | 2.92 (0.19) | 2.41 (0.07) | 0.02 |
| Tumor stage (% T1) | |||
| Median (range) | 57% (0, 90%) | 71% (0, 100%) | 0.05 |
| % BEDperiphery ≥ 100 Gy10 | 50% | 63.6% | 0.62 |
| Tumor location (% P only) | 30% | 28.6% | 0.93 |
*
2 studies reporting on the same phase II trial and 1 study and 1 abstract reporting on the same phase II trial in a complementary manner were counted as 1 single study each. The p value was obtained with the meta-regression model weighted by sample size described in Supplementary materials, using statistical software R with the statistical package “Meta” [18,19].